
    
      This is a prospective randomized doubleblind controlled trial involving 660 consenting
      pregnant women. Eligible subjects will be ransomised into 2 groups of 330 participants. All
      patients will receive the standard oxytocin 10 units as part of the active management of
      third stage of labour. However, the study group will be administered sublingual 400
      misoprostol while the control group will receive 2tablets of placebo (vitamin c). Measured
      mean blood loss will be comparee in the 2 groups using statistical analysis.
    
  